PECAM1 and familial dilated cardiomyopathy: Quantitative analysis of immunoblots showed that PECAM-1 increased 3.16-fold in DCM patients, 3.4-fold in MYO patients and 2.97-fold in patients with ICM compared to the control group (Fig. 8C).